However, several of these studies were limited by a low number of patients included7,8, or by the fact that the prognostic role of HER2 status was evaluated in heterogeneous patient cohorts, i.e., in patients with different tumor biology and receiving different types of systemic therapies6,9. This evidence concerns the gene ERBB2 and neoplasm.